CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.94−0.05 (-2.27%)
Close on Nov 17, 2026Market cap $422.73MP/E –Yield –
CytomX Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
CytomX Therapeutics's pe ratio was 14.2× on Jan 30, 2026, against 5.0× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jan 30, 2026 | 14.2× | +3.6 |
| 2025 | Dec 31, 2025 | 10.7× | +4.6 |
| 2024 | Dec 31, 2024 | 6.1× | – |
See a number that looks wrong?